Importantly, by sparing peripheral cells—including peripheral, non‐CNS endothelial cells—gene therapy with the AAV‐BR1 vector obviates potential adverse effects that have been attributed to NEMO, such as promoting atherosclerosis (Gareus et al, 2008). This evidence concerns the gene IKBKG and atherosclerosis.